Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 7, 2010

View Archived Issues

Roche discovers new inverse agonists of GABA(A) alpha5 receptor

Merck KGaA divulges novel inhibitors of protein kinases

Preliminary efficacy reported in first-in-human trial of LFB-R603 in chronic lymphocytic leukemia

Interim data from phase I trial of PF-03732010 in advanced solid tumors reveal good tolerability

Oncolytic prodrug BMS-817378 selected for clinical development

Activity seen with ARRY-520 in patients with relapsed/refractory multiple myeloma

ACT Biotech describes activity of Aurora kinase inhibitor ACTB-1010

Phase II results for plitidepsin in peripheral T-cell lymphoma presented

The Leukemia and Lymphoma Society provides support to BioTheryX

Case Western Reserve University licenses insulin analogues to Thermalin Diabetes

MorphoSys and Xencor start phase I study of MOR-208 in chronic lymphocytic leukemia

Cell Therapeutics appeals FDA decision on pixantrone NDA for non-Hodgkin's lymphoma

Cyrenaic reports results from phase IIa CYR-101 trial in schizophrenia

Agios Pharmaceuticals describes novel pyruvate kinase M2 activators

Insmed and Transave enter into business combination

Geron begins phase II imetelstat trial in breast cancer

Forest Laboratories discloses novel acetyl-CoA carboxylase inhibitors

New antibacterials created by UMDNJ and Rutgers scientists

BioMarin receives U.K. approval for clinical trial of BMN-673 in genetically defined cancers

Cynapsus reports data for Parkinson's drug candidate APL-130277

QR Pharma cleared to conduct clinical trials with bisnorcymserine for AD

Long-term phase III study confirms efficacy of avanafil for erectile dysfunction

Prochieve 8% reduces incidence of preterm birth in phase III study

FDA accepts for review sBLA for subcutaneous Orencia

Pfizer plans 2011 regulatory submissions for bosutinib in CML

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...